Hypermethylated Genes of MicroRNA in Ovarian Carcinoma: Metastasis Prediction Marker Systems


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

We identified a group of miRNA genes whose methylation is associated with ovarian cancer metastasis. Based on these data, new markers and the systems of markers predicting tumor dissemination were selected. Using methylation-specific PCR and a representative set of 54 ovarian cancer samples, we identified 10 microRNA genes (MIR-124a-2, MIR-127, MIR-125b-1, MIR-129-2, MIR-137, MIR-193a, MIR-203a, MIR-34b/c, MIR-130b, and MIR-1258) whose methylation is associated with tumor metastasis. The greatest association was established for 4 genes: MIR-137, MIR-193a, MIR-34b/c, and MIR-130b (p<0.01). ROC analysis revealed 3 most optimal marker systems including 4-5 miRNA genes and characterized by high sensitivity (82-94%) and specificity (76-86%) at AUC=0.89-0.92. Methylation of any three genes from these systems is sufficient to predict metastasis with the specified accuracy. Detection of the group of hypermethylated miRNA genes with predictive value for ovarian cancer metastasis is of great importance for personalized treatment of the patients.

Sobre autores

E. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Rússia, Moscow

V. Loginov

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

Email: eleonora10_45@mail.ru
Rússia, Moscow; Moscow

A. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Rússia, Moscow

E. Braga

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

Autor responsável pela correspondência
Email: eleonora10_45@mail.ru
Rússia, Moscow; Moscow

I. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Rússia, Moscow

T. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Rússia, Moscow

D. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Rússia, Moscow

D. Utkin

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Rússia, Moscow

M. Fridman

N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences

Email: eleonora10_45@mail.ru
Rússia, Moscow

D. Khodyrev

Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia

Email: eleonora10_45@mail.ru
Rússia, Moscow

N. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Rússia, Moscow

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2019